CDX
SNU-5
Tumor indication
Gastric
Tumor subtype
Gastric carcinoma
Description
SNU-5 (Gastric Cancer CDX Model)
The SNU-5 gastric cancer cell line was established from a patient with poorly differentiated gastric carcinoma. It represents advanced stomach cancer biology. SNU-5 is widely applied in preclinical drug testing and biomarker research. Its reproducible growth makes it a useful gastric cancer research tool.
Key Features:
- Derived from poorly differentiated gastric carcinoma.
- Represents aggressive stomach cancer.
- Epithelial morphology.
- Tumorigenic in xenografts.
Applications:
SNU-5 is used to evaluate novel therapies for gastric cancer. Researchers apply it in biomarker discovery and resistance mechanism studies. It supports screening of targeted agents in stomach cancer. Its reproducibility ensures reliability in translational pipelines.
Details
- Tumor indication
- Gastric
- Tumor subtype
- Gastric carcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.